Current treatment in myeloproliferative disorders.
| . | . | . | Myelofibrosis . | |
|---|---|---|---|---|
| Risk Categories . | Essential Thrombocythemia . | Polycythemia Vera . | Age < 50 years . | Age ≥ 50 years . |
| *Clinically significant acquired von Willebrand disease should be excluded before the use of aspirin in patients with platelet count over 1000 X 109/L. | ||||
| Abbreviations: RIC, reduced-intensity conditioning | ||||
| Low | Low-dose aspirin | Low-dose aspirin + Phlebotomy | Observation or Experimental drug therapy | Observation or Experimental drug therapy |
| Intermediate | Low-dose aspirin* | Low-dose aspirin* + Phlebotomy | Experimental drug therapy or RIC transplant | Experimental drug therapy or Conventional therapy |
| High | Low-dose aspirin + Hydroxyurea | Low-dose aspirin + Phlebotomy + Hydroxyurea | Experimental drug therapy or Full transplant | Experimental drug therapy or RIC transplant |
| . | . | . | Myelofibrosis . | |
|---|---|---|---|---|
| Risk Categories . | Essential Thrombocythemia . | Polycythemia Vera . | Age < 50 years . | Age ≥ 50 years . |
| *Clinically significant acquired von Willebrand disease should be excluded before the use of aspirin in patients with platelet count over 1000 X 109/L. | ||||
| Abbreviations: RIC, reduced-intensity conditioning | ||||
| Low | Low-dose aspirin | Low-dose aspirin + Phlebotomy | Observation or Experimental drug therapy | Observation or Experimental drug therapy |
| Intermediate | Low-dose aspirin* | Low-dose aspirin* + Phlebotomy | Experimental drug therapy or RIC transplant | Experimental drug therapy or Conventional therapy |
| High | Low-dose aspirin + Hydroxyurea | Low-dose aspirin + Phlebotomy + Hydroxyurea | Experimental drug therapy or Full transplant | Experimental drug therapy or RIC transplant |